Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android

For instructor materials including Power Points, Answers to Clinical Encounter Questions, please contact

Content Update

March 7, 2020

Tazemetostat Approved for Treatment of Sarcoma: Tazemetostat (Tazverik) is the first EZH2 inhibitor approved by the FDA and is indicated for adults and children older than 16 for the treatment of epithelioid sarcoma. In a phase II, open-label trial of patients with locally-advanced or metastatic epithelioid sarcoma, 62 patients were treated with tazemetostat 800 mg orally twice a day. The disease control rate (defined as complete responses, partial response and stable disease) was 26% (15/62) with a median overall survival of 82.4 weeks (95% CI: 47.4, not estimable) for all 62 pts. Tazemetostat was well tolerated; the most common adverse effects were fatigue and nausea.



Upon completion of the chapter, the reader will be able to:

  1. Discuss the underlying pathophysiologic mechanisms of the lymphomas and how they relate to presenting symptoms of the disease.

  2. Differentiate the pathologic findings of Hodgkin lymphoma (HL), follicular indolent non-Hodgkin lymphoma (NHL), and diffuse aggressive NHL and how this information yields a specific diagnosis.

  3. Describe the general staging criteria for the lymphomas and how it relates to prognosis; evaluate the role of the prognostic systems such as the International Prognostic Score for HL, the Follicular Lymphoma International Prognostic Index (IPI), and the IPI for diffuse, aggressive NHL.

  4. Compare and contrast the treatment algorithms for early and advanced stage disease for HL.

  5. Assess the role of autologous hematopoietic stem cell transplantation for relapsed lymphomas.

  6. Delineate the clinical course of follicular indolent and diffuse aggressive NHL and the implications for disease classification schemes and treatment goals.

  7. Outline the general treatment approach to follicular indolent and diffuse aggressive NHL for localized and advanced disease.

  8. Interpret the current role for monoclonal antibody therapy in NHL.


The malignant lymphomas are a clonal disorder of hematopoiesis with the primary malignant cells consisting of lymphocytes of B-, T-, or natural killer (NK) cell origin. Lymphoma cells predominate in the lymph nodes; however, they can infiltrate lymphoid and nonlymphoid tissues, such as the bone marrow, central nervous system (CNS), gastrointestinal (GI) tract, liver, mediastinum, skin, and spleen. An overview of the lymph node regions is depicted in Figure 97–1. image There are two broad classifications of lymphoma, Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), and both contain numerous histologic subtypes that are pathologically distinct disease entities.

FIGURE 97–1.

Representation of the anatomic regions used in the staging of Hodgkin disease. (From Rosenberg SA. Staging of Hodgkin disease. Radiology. 1966;87:146.)

The clinical course varies widely among histologies of lymphoma. More aggressive subtypes are highly proliferating cells that require aggressive therapeutic intervention with chemotherapy, radiation therapy, or both. By contrast, certain subtypes of NHL are characterized by a disease course that flares ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.